Abstract Submission

Submission Period:
January 4 (Mon), 2021 - April 1 (Thu), 2021 April 14 (Wed), 2021 Extended
Submission Closed

Important Notes
After submitting your abstract, the accepted abstracts will be posted for the on-demand online streaming. The secretariat will further contact you after the abstract acceptance notification, however, please note in advance that we will request the creation of slides with audio as mp4 video files.

How to Submit

Please select “Submit Now” on the bottom of this page to start the submission process.

  • * You must create your profile account first to submit an abstract. If you already have one for registration, please start from log-in.

Abstract Submission Guidelines

  • Only create one account for abstract submission
  • Up to 3 submissions are allowed per person
  • 300 words count limit
  • Select your presentation preference, oral or poster presentation
  • Select your presentation style, possibly onsite presentation, possibly remote presentation, or on-demand presentation later.
    If you select poster presentation, choose on-demand presentation.
  • Include all authors and affiliations in submission, including the submitting author, any co-authors and speaker (with email).
  • All abstracts must be submitted and presented in English with spelling and grammar of a quality suitable for publication
  • All submissions will be printed the exact way they are submitted
  • Choose a topic you think appropriate from below:
    • ・Epidemiology
    • ・Viral latency
    • ・Viral replication and reactivation
    • ・Viral pathogenesis, tumorigenesis and microenvironment
    • ・Virus-Host interaction and immunity
    • ・Burkitt lymphoma, Hodgkin's lymphoma, and B-cell lymphomas
    • ・Chronic active EBV infection, Hydroa vacciniforme, Mosquito bite allergies
    • ・Post-transplant lymphoproliferative disease
    • ・NK/T lymphoproliferative diseases/lymphomas
    • ・Nasopharyngeal carcinoma, gastric carcinoma, and other epithelial cell cancer
    • ・Novel or Other EBV-associated diseases/malignancies
    • ・Vaccine Formulation and Therapeutics
    • ・Clinical Case Reports
    • ・Others

Review Procedures

Result has been sent to the corresponding author.

If you have NOT received it, please email us (ebv2020-paper@issjp.com)

  • All submittals are reviewed by the conference program committee
  • Proposals constituting sales pitches for products or services will not be considered
  • Topic may be changed from your choice according to program committee's decision
  • Any oral submissions not chosen for an oral presentation will receive a poster presentation